Known targets — ChEMBL curated mechanism
ADRB1CDK4CDK6CHRM2CHRM3DPP4DRD2DRD3DRD4EGFRHRH1HTR1BHTR1DHTR1FHTR2AHTR2CHTR4SLC6A2SLC6A4
The experimentally established mechanism targets of Cevipabulin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | NSD2 | O96028 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cevipabulin SCHEMBL4211390 | 1.00 | ENPP1 (0.34) | ENPP1HSD17B10ALDH1A1KDM4ENSD2 | |
| Cevipabulin SCHEMBL4216639 | 0.99 | ENPP1 (0.34) | ENPP1HSD17B10ALDH1A1KDM4ENSD2 | |
| Cevipabulin SCHEMBL5755942 | 0.94 | MBOAT4 (0.34) | ALDH1A1MBOAT4POLBTSHRKMT2A | |
| Cevipabulin SCHEMBL4565043 | 0.94 | ALDH1A1 (0.31) | ENPP1ALDH1A1KDM4ENSD2SMN1; SMN2 | |
| Cevipabulin SCHEMBL4219378 | 0.94 | ALDH1A1 (0.31) | ENPP1ALDH1A1KDM4ENSD2SMN1; SMN2 | |
| Cevipabulin SCHEMBL4222922 | 0.94 | ALDH1A1 (0.31) | ENPP1ALDH1A1KDM4ENSD2SMN1; SMN2 | |
| Cevipabulin SCHEMBL4565044 | 0.94 | ALDH1A1 (0.31) | ENPP1ALDH1A1KDM4ENSD2SMN1; SMN2 | |
| Cevipabulin SCHEMBL4477222 | 0.94 | MBOAT4 (0.34) | ALDH1A1MBOAT4POLBTSHRKMT2A | |
| Cevipabulin SCHEMBL4042827 | 0.94 | MBOAT4 (0.34) | ALDH1A1MBOAT4POLBTSHRKMT2A | |
| Cevipabulin SCHEMBL4484813 | 0.94 | MBOAT4 (0.34) | ALDH1A1MBOAT4POLBTSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7507739-B2 | 6-[(substituted)phenyl]triazolopyrimidines as anticancer agents | WYETH (US) | 2009-03-24 | — | — | US | disclosed |
| US-7419982-B2 | Crystalline forms of 5-chloro-6-{2,6-difluoro-4-[3-(methylamino)propoxy]phenyl}-N-[(1S)-2,2,2-trifluoro-1-methylethyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine salts | WYETH HOLDINGS CORPORATION (US) | 2008-09-02 | — | — | US | disclosed |
| US-20070060597-A1 | Crystalline forms of 5-Chloro-6-{2,6-difluoro-4-[3-(methylamino)propoxy]phenyl}-N-[(1S)-2,2,2-trifluoro-1-methylethyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine salts | WYETH (US) | 2007-03-15 | — | — | US | disclosed |
| EP-1680425-B1 | 6- [(SUBSTITUTED)PHENYL] TRIAZOLOPYRIMIDINES AS ANTICANCER AGENTS | WYETH CORP (US) | 2007-01-10 | — | — | EP | disclosed |
| EP-1680425-A1 | 6- [(SUBSTITUTED)PHENYL] TRIAZOLOPYRIMIDINES AS ANTICANCER AGENTS | Wyeth Holdings Corporation (US) | 2006-07-19 | — | — | EP | disclosed |
| US-20050090508-A1 | 6-[(Substituted)phenyl]triazolopyrimidines as anticancer agents | WYETH HOLDINGS CORPORATION (US) | 2005-04-28 | — | — | US | disclosed |
| WO-2005030775-A1 | 6-[(SUBSTITUTED)PHENYL]TRIAZOLOPYRIMIDINES AS ANTICANCER AGENTS | WYETH HOLDINGS CORPORATION (US) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090508-A1 | 6-[(Substituted)phenyl]triazolopyrimidines as anticancer agents | ABCC1, ABCB1, TUBB6 | ENPP1 1978/4885HSD17B10 4712/4885ALDH1A1 1838/4885 |
| US-20070060597-A1 | Crystalline forms of 5-Chloro-6-{2,6-difluoro-4-[3-(methylamino)propoxy]phenyl}-N-[(1S)-2,2,2-trifluoro-1-methylethyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine salts | HCCS, TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | ENPP1 1502/4885HSD17B10 4650/4885ALDH1A1 971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.